Vanda Pharmaceuticals said Monday that it expects to report total net product sales from Hetlioz and Fanapt of approximately $38 million for Q4, and approximately $146 million for full year 2016. The Street estimates call for total revenues of $39.7 million and $147.5 million for Q4 and 2016, respetively.
For 2017, the company expects net product sales from Hetlioz and fanapt of between $165 million and $175 million. Cash is expected to decline by $20 million during 2017. The Street consensus calls for 2017 revenues of $183.8 million. Shares were 3.4% lower in recent morning trade.